title: [Use of cycloferon in the treatment of patients with pulmonary tuberculosis with mild clinical manifestations].
abstract: OBJECTIVE
  to evaluate the efficacy of cyclopheron used in patients with mild clinical manifestations of focal and infiltrative pulmonary tuberculosis (PT).
  
  
  METHODS
  Thirty first detected patients with PT, in whom a complex of their etiotropic therapy comprised cyclopheron, and 32 similar patients who received etiotropic agents and placebo were examined. Tuberculosis process activity was confirmed by clinical, X-ray, bacteriological, and immunological studies. The hypothalamic-pituitary-adrenal system was determined from serum cortisol concentration. The sympathoadrenal system was assessed from cardiac rhythm parameters (autonomic balance index).
  
  
  RESULTS
  Incorporation of cyclopheron into the combined therapy of patients with PT led to increased blood cortisol concentration, higher autonomic balance index, elevated T-lymphocyte count, enhanced phagocytic activity, and lower levels of circulating immune complexes, resulting in earlier decay cavity closure and sputum negativation.
  
  
  CONCLUSIONS
  Extrastress status of adaptation systems and the absence of their activating impact on immunity and inflammation are detectable in first detected patients with mild clinical manifestations of PT running in significant lung tissue fibrosis. Therapy with cyclopheron that stimulates the production of stress-induced cytokines gives rise to a stress reaction, activates immune processes, and enhances therapeutic effectiveness in this group of patients.
authors.forename: T P
authors.initials: TP
authors.lastname: Filippova
authors.forename: L S
authors.initials: LS
authors.lastname: Vasil'eva
authors.forename: A V
authors.initials: AV
authors.lastname: Kochkin
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D008297:Male; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000166:Acridines; D000995:Antitubercular Agents; D007155:Immunologic Factors; C026430:10-carboxymethyl-9-acridanone